SCHEMBL11064146

SCHEMBL11064146

CC(C)NC(=O)C(C)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17207576 1.00
SCHEMBL10677092 0.82
SCHEMBL10677690 0.78
SCHEMBL10535057 0.76 ALDH1A1 (0.44)
SCHEMBL142029 0.75
SCHEMBL19000042 0.74 CA12 (0.39)
SCHEMBL12545610 0.74 CA12 (0.39)
SCHEMBL19000044 0.74 CA12 (0.39)
SCHEMBL11071385 0.74 MMP1 (0.48)
SCHEMBL8926052 0.74 TSHR (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212164-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-07-06 US disclosed
US-20230212164-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-07-06 US disclosed
WO-2021112251-A1 AZETIDINE SULFONAMIDE COMPOUND 第一三共株式会社 2021-06-10 WO disclosed
US-10988484-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2021-04-27 US disclosed
US-10988484-B2 Glucose uptake inhibitors KADMON CORPORATION, LLC (US) 2021-04-27 US disclosed
US-10676433-B2 Indole derivatives and their use in neurodegenerative diseases MERCK PATENT GMBH (DE) 2020-06-09 US disclosed
US-20190315772-A1 GLUCOSE UPTAKE INHIBITORS KADMON CORP LLC (US) 2019-10-17 US disclosed
US-20190315772-A1 GLUCOSE UPTAKE INHIBITORS KADMON CORP LLC (US) 2019-10-17 US disclosed
US-10323000-B2 Indole derivatives and their use in neurodegenerative diseases MERCK PATENT GMBH (DE) 2019-06-18 US disclosed
US-20190161447-A1 NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2019-05-30 US disclosed
US-20180298029-A1 GLUCOSE UPTAKE INHIBITORS KADMON CORPORATION LLC (US) 2018-10-18 US disclosed
EP-3313825-A1 GLUCOSE UPTAKE INHIBITORS Kadmon Corporation, LLC (US) 2018-05-02 EP disclosed
US-20180111956-A1 SYNTHESIS OF DESOSAMINES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-04-26 US disclosed
US-20180066008-A1 MACROLIDES WITH MODIFIED DESOSAMINE SUGARS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-03-08 US disclosed
EP-3233841-A1 INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES Merck Patent GmbH (DE) 2017-10-25 EP disclosed
WO-2016210330-A1 GLUCOSE UPTAKE INHIBITORS KADMON CORPORATION, LLC (US) 2016-12-29 WO disclosed
WO-2016100281-A1 INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2016-06-23 WO disclosed
US-20160168090-A1 NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES MERCK PATENT GMBH (DE) 2016-06-16 US disclosed
US-4478838-A VASODILATOR AGENTS HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1984-10-23 US disclosed
EP-0083712-A1 1-(3,4,5-Trimethoxycinnamoyl)-4-aminocarbonylethyl-substituted piperazine derivatives and a process for the preparation thereof Hokuriku Pharmaceutical Co.,Ltd (JP) 1983-07-20 EP disclosed